Compare Citius Pharmaceuticals Inc (CTXR) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares MBS ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while iShares MBS ETF trades at $89.7 (market cap $35.41B). The key difference: iShares MBS ETF is far larger — about 2599.9× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 5,388,525). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and iShares MBS ETF for 96 Days on average.
| CTXR | MBB | |
|---|---|---|
Market Cap | $13.62M | $35.41B |
Volume | 132,438 | 5,388,525 |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $96.91 |
52-Week Low | $0.48 | $89.09 |
Typical Hold Time | 16 Days | 96 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
MBB (iShares MBS ETF) trades at $89.22, down 0.16% amid bearish technical signals with 18 sell indicators versus 2 buy signals. The ETF faces pressure from rising intermediate-term rates and inflation concerns, with short interest surging 98.3% in September 2026 to 6.57 million shares. Recent institutional activity shows mixed sentiment with some firms increasing positions while technical indicators point to continued downward momentum.
The outlook remains challenging with convexity risk and borrower prepayment optionality limiting upside potential. Investment opportunity exists for income-focused investors through consistent dividend payments, but risks include duration exposure during potential rate hikes and persistent inflation pressures affecting mortgage-backed securities performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
